Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1510)	10/1/2015 9:13:49 AM
From: oldcoach19	Read Replies (2) \| Respond to of 2026

I called Matt Beck this morning for further clarification. Will report back when he returns my call.

To: phoenix_rising who wrote (1510)	10/1/2015 10:28:19 AM
From: Mirror Image	Read Replies (1) \| Respond to of 2026

It has been public information since the August Conference Call. Sandoz sold out all their Vitaros units in Germany and has not re-ordered in that country - in August. Let me guess. The doom and gloom party is out in force in the other boards ( IHUB, Yahoo, etc )? Sandoz has many other countries partnered to sell Vitaros in and has continued to re-order and sell in Belgium and Sweden, even as this event is investigated. On the other hand, Germany is one of the BIG markets in Europe. But if we look at the old Vitaros sales numbers, it wasn't like they were having a BIG impact. Management ( Pascoe ) mentioned that Majorelle and Recordati were having a BIG impact because they went after the first line users in their respective countries vs. the hard to treat populations that Sandoz and Takeda targeted. My guess is that Sandoz is probably going to change their strategy in Germany. And they might wait for the room temperature version to do it. I have not spoke to anybody - it's just a guess! Same scenario with Canada - not launching the cold version - will wait for room temperature ( we came up with that scenario on this board - a very long time ago ).

To: phoenix_rising who wrote (1510)	10/2/2015 2:10:00 AM
From: Mirror Image	Read Replies (1) \| Respond to of 2026

This press release is rather vague, there is no mention of double digit royalties, so safe to assume it is single digit. Item 8.01. Other Events. On October 1, 2015, Apricus Biosciences, Inc. (the “Company”), through its wholly-owned subsidiary NexMed (U.S.A.), Inc., entered into a distribution agreement with Ferring International Center S.A. (“Ferring Pharmaceuticals”), whereby the Company granted Ferring Pharmaceuticals exclusive rights to market the Company’s Vitaros™ drug for the treatment of erectile dysfunction in Latin American countries, including Central America, South America and certain Caribbean countries (the “Territory”). Under the terms of the agreement, the Company will receive an upfront payment of $2.25 million from Ferring Pharmaceuticals. The Company is also eligible to receive up to $16 million in regulatory and sales milestone payments, plus high single-digit royalties based on Ferring Pharmaceutical’s net sales of the product in the Territory. Ferring Pharmaceuticals has agreed to obtain all necessary regulatory marketing approvals.